Abstract
Objective: To evaluate clinical, Quality of Life (QoL) and medical cost outcomes in patients with symptomatic reflux esophagitis (RE) receiving different “triple combination therapy”. Methods: A multicenter medical effectiveness trial conducted in 10 hospitals of 5 regions in Zhejiang Province. 248 patient-volunteers were assigned to 8 weeks of “triple combination therapy” with Lansoprazole plus Cisapride and Sucralfate or Ranitidine plus Cisapride and Sucralfate. Main outcomes assessment included symptoms scale scores, RE severity, QoL at baseline and 8 weeks. Medical cost data were collected with cost analysis questionnaire. Results: (1) More Lansoprazole group patients noted RE symptoms resolution than Ranitidine group (92.3% vs 78.4%,P<0.01). There was no striking difference between two groups in RE healing rate (90.8% vs 82.9%,P>0.05). (2) RE significantly impaired QoL of patients (P<0.001). Compared with Ranitidine group, QoL in Lansoprazole group had significant improvement (rate of “good” QoL 64.5% vs 45.6%,P<0.01). (3) There was close correlation between symptomic effectiveness and QoL rating scale in both the Lansoprazole and Ranitidine group (P<0.01,r=0.235 and 0.353 respectively). There were no statistical difference of medical cost between the two groups (P>0. 05). Conclusion: RE significantly impaired QoL of patients. “Triple combination therapies” can significantly improve RE symptoms and QoL. Lansoprazole combination therapy was more cost-effective than Ranitidine combination group.
Similar content being viewed by others
References
Bloom, B. S., Hillman, A. L. and Lammont, B., 1995. Omeprazole or ranitidine plus metoclopramide for patients with severe esophagitis: a cost-effetiveness analysis.Pharmacoeconomic,8: 343–349.
Devault, K. R. and Castell, D. O., 1995. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease.Arch. Intern. Med.,155: 2165–2173.
Hawden, C. W., Castell, D. O., and Cohen, S., 1995. The rational for continuous maintenance treatment of reflux esophagitis.Arch. Intern. Med.,155: 1465–1471.
Mathias, S. D., Castell, D. O. and Elkin, E. P., 1996. Health-related quality of life of patients with acute erosive reflux esophagitis.Dis Sci.,41: 2123–2123.
McDougall, N. I., Johnston, B. T. and Kee, F., 1996. Natural history of reflux oesophagitis: a 10-year followup of its effect on patients symptomatology and quality of life.Gut.,38: 481–486.
Mckenna, C. J., Mills, J. G. and Gooduin, C., 1995. Combination of ranitidine and cisapride in the treatment of reflux oeseophagitis.Eur. J. Gastroenterol Hepatol,7: 817–822.
Pan, G. Z., Xu, G. M. and Guo, H. P., 1999. An epidemiologic study on gastroesophageal reflux symptoms in Beijing and Shanghai.Chinese Journal of Digestion,19: 223–226 (in Chinese with English abstract).
Vic, Velanovich, 2000. Quality of life and severity of symptoms in gastro-oesophageal reflux disease: a clinical review.Eur. J. Surg.,166:516–525.
Vigneri, S., Termini, R. and Leandro, G., 1995. A comparison of five maintenance therapies for reflux esophagitis.J. Eng. J. Med.,333: 1106–1110.
Yang, L., Li, C. Y. and Wu, J. C., 1997. Study of effectiveness of ranitidine plus cisapride compared ranitidine for GERD.Chinese Journal of Endoscopy,3: 9–10 (in Chinese with English abstract).
Zagari, M., Villa, K. F. and Freston, J. W., 1995. Proton pump inhibitors versus H2-receptor anatogonists fot the treatment of erosive gastroesophageal reflux disease: A cost comparative study.Am. J. Man. Care.,1: 247–255.
Author information
Authors and Affiliations
Additional information
Project (No. 200A074) supported by the Zhejiang Province Health Bureau, China
Rights and permissions
About this article
Cite this article
Jian-min, S., Liang-jing, W., Shu-jie, C. et al. Quality of life and cost-effectiveness of combined therapy for reflux esophagitis. J. Zhejiang Univ. Sci. A 4, 602–606 (2003). https://doi.org/10.1631/jzus.2003.0602
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.2003.0602